|
US9359447B2
(en)
*
|
2012-03-23 |
2016-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
US9409992B2
(en)
*
|
2012-08-21 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2016133829A1
(en)
*
|
2015-02-17 |
2016-08-25 |
Full Spectrum Genetics, Inc. |
Novel sd1 binding compounds and uses thereof
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
CN106467573B
(zh)
*
|
2015-08-21 |
2021-05-25 |
佧珐药业有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
CA3289997A1
(en)
|
2015-09-20 |
2026-03-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
CN116987189A
(zh)
|
2016-05-20 |
2023-11-03 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
KR20190022632A
(ko)
|
2016-06-20 |
2019-03-06 |
에프-스타 베타 리미티드 |
Lag-3 결합 구성원
|
|
EP3494135A1
(en)
*
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
EP3544629A4
(en)
|
2016-11-23 |
2020-06-17 |
Harpoon Therapeutics, Inc. |
PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
|
|
CN110198955A
(zh)
|
2016-11-23 |
2019-09-03 |
哈普恩治疗公司 |
前列腺特异性膜抗原结合蛋白质
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
AU2017382883B2
(en)
|
2016-12-21 |
2024-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
CN110612119B
(zh)
|
2017-02-07 |
2024-10-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
|
|
JP7137896B2
(ja)
*
|
2017-03-24 |
2022-09-15 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法
|
|
AU2018265856B2
(en)
*
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
WO2018209304A1
(en)
*
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
WO2018213612A1
(en)
*
|
2017-05-18 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
|
WO2018213064A1
(en)
|
2017-05-19 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
|
|
EP3638295A1
(en)
|
2017-06-13 |
2020-04-22 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
US20200197547A1
(en)
*
|
2017-08-30 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers
|
|
HRP20241268T1
(hr)
|
2017-10-13 |
2024-12-06 |
Harpoon Therapeutics, Inc. |
Trispecifični proteini i postupci primjene
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
|
CN111683962B
(zh)
|
2017-11-10 |
2025-05-16 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向肿瘤抗原的嵌合抗原受体
|
|
WO2019118760A1
(en)
*
|
2017-12-13 |
2019-06-20 |
Inovio Pharmaceuticals, Inc. |
Cancer vaccines targeting mesothelin and uses thereof
|
|
CN108129566B
(zh)
*
|
2017-12-31 |
2021-05-11 |
中国科学院武汉病毒研究所 |
靶向间皮素的c-型单域抗体及其制备方法与应用
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
SG11202007426XA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
WO2019178546A1
(en)
|
2018-03-16 |
2019-09-19 |
Scipher Medicine Corporation |
Methods and systems for predicting response to anti-tnf therapies
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
EP3806889A4
(en)
*
|
2018-06-18 |
2022-07-13 |
Anwita Biosciences, Inc. |
CYTOKI FUSION PROTEINS AND USES THEREOF
|
|
PL3820569T3
(pl)
|
2018-07-12 |
2025-07-14 |
Invox Pharma Limited |
Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
EP3820903A1
(en)
|
2018-07-12 |
2021-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
BR112021000282A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a cd137 e ox40
|
|
GB201811450D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
CN112585163B
(zh)
|
2018-08-08 |
2025-03-25 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
|
SG11202101773WA
(en)
*
|
2018-08-29 |
2021-03-30 |
Nanjing Legend Biotech Co Ltd |
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
|
WO2020047501A1
(en)
|
2018-08-30 |
2020-03-05 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
SG11202103022WA
(en)
|
2018-09-25 |
2021-04-29 |
Harpoon Therapeutics Inc |
Dll3 binding proteins and methods of use
|
|
CN109406765B
(zh)
*
|
2018-10-23 |
2022-02-01 |
大连博格林生物科技有限公司 |
细胞增殖与毒性检测试剂盒
|
|
US12180296B2
(en)
|
2019-01-08 |
2024-12-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting mesothelin for treating solid tumors
|
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
WO2020204305A1
(ko)
*
|
2019-03-29 |
2020-10-08 |
주식회사 녹십자 |
항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
GB2603294A
(en)
|
2019-06-27 |
2022-08-03 |
Scipher Medicine Corp |
Developing classifiers for stratifying patients
|
|
CN114729041B
(zh)
|
2019-10-22 |
2024-12-31 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
|
|
JP7657213B2
(ja)
*
|
2019-11-07 |
2025-04-04 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
|
|
AU2021217003A1
(en)
|
2020-02-04 |
2022-09-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Anti-dinitrophenol chimeric antigen receptors
|
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
EP4175650A1
(en)
*
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
EP4263612A4
(en)
*
|
2020-12-18 |
2025-04-02 |
Bioardis LLC |
Mesothelin binding molecules and uses thereof
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
WO2022235295A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
US20240270851A1
(en)
|
2021-06-09 |
2024-08-15 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
WO2023051414A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
北恒医疗有限公司 |
靶向间皮素的抗体及其用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
TW202323281A
(zh)
*
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
間皮素結合蛋白及其用途
|
|
AU2022366987A1
(en)
|
2021-10-14 |
2024-05-16 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
EP4448566A1
(en)
|
2021-12-17 |
2024-10-23 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
|
|
CN116410332B
(zh)
*
|
2021-12-29 |
2025-04-15 |
上海细胞治疗集团股份有限公司 |
抗间皮素纳米抗体嵌合抗原受体及其应用
|
|
EP4461747A4
(en)
*
|
2022-01-06 |
2026-04-15 |
Oricell Therapeutics Co Ltd |
ANTIGEN-BINDING PROTEIN TARGETTING MSLN AND ITS USE
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
US20260071003A1
(en)
|
2022-09-01 |
2026-03-12 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN116003638B
(zh)
*
|
2023-01-20 |
2023-09-05 |
北京基因启明生物科技有限公司 |
一种有效杀伤胆管型肝癌的CAR-iNKT细胞技术
|
|
EP4662244A1
(en)
*
|
2023-02-06 |
2025-12-17 |
Université d'Aix Marseille |
Anti-mesothelin nanobodies, constructs and conjugates
|
|
CN121038806A
(zh)
|
2023-04-25 |
2025-11-28 |
阿森纳生物科学公司 |
用于转录调控的新颖受体
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
CN116751300A
(zh)
*
|
2023-06-15 |
2023-09-15 |
上海斯丹赛生物技术有限公司 |
抗间皮素重链单域抗体及其在癌症治疗中的应用
|
|
AU2024295016A1
(en)
|
2023-07-20 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025063790A1
(ko)
*
|
2023-09-20 |
2025-03-27 |
주식회사 유씨아이테라퓨틱스 |
항-메소텔린 항체 및 이의 용도
|
|
WO2025143287A1
(ko)
*
|
2023-12-27 |
2025-07-03 |
서울대학교산학협력단 |
메소텔린에 특이적인 항체 및 이의 용도
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|